Compare PRAA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAA | LAB |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.5M | 449.9M |
| IPO Year | N/A | 2011 |
| Metric | PRAA | LAB |
|---|---|---|
| Price | $16.57 | $1.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $24.33 | $1.35 |
| AVG Volume (30 Days) | 495.0K | ★ 2.1M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,161,679,000.00 | $169,737,000.00 |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.41 | ★ 79.77 |
| 52 Week Low | $12.29 | $0.92 |
| 52 Week High | $23.97 | $2.25 |
| Indicator | PRAA | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 62.93 |
| Support Level | $15.70 | $1.28 |
| Resistance Level | $16.57 | $1.56 |
| Average True Range (ATR) | 0.67 | 0.09 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 94.44 | 70.00 |
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.